Process for preparing 1,3-dioxane derivatives or salts thereof

专利摘要:
A compound of the formula : <CHEM> wherein R<1> is hydrogen or lower alkyl, R<2> is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R<3> is -CH2NH-R<4>, -CH=N-R<4> or -CH2-R<5> in which R<4> is acyl, acylamino, heterocyclic amino, heterocyclic(lower)alkyl or ar(lower)alkoxy and R<5> is acyloxy or heterocyclic(lower)alkoxy and X is -O- or -CH2-, or pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them as an active ingredient.
公开号:SU1731054A3
申请号:SU884356081
申请日:1988-07-05
公开日:1992-04-30
发明作者:Сетой Хироюки；Курода Акио；Танака Хироказу；Хирай Хидео；Марусава Хироси；Хасимото Масаси
申请人:Фудзисава Фармасьютикал Ко., Лтд.(Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of new derivatives of 1,3-dioxane or their salts, which are. antagonists of thromboxane Ar (THA2) and can be used for treatment. THA2 diseases,
The purpose of the invention is the production of new derivatives of 1,3-dioxane, which have a higher inhibitory activity against platelet aggregation.
The method is carried out as follows.
A mixture of (2R, 4S, 5K) -5-hydroxy-4-hydroxymethyl-2-methyl-1,3-dioxane (13.0 g), tert-butyldimethylchlorosilane (14.5 g) and imidazole (13.1 g) in M, I-dimethyl formamide (130 ml) was stirred at room temperature for 2 hours and this mixture was diluted with ethyl acetate (500 ml). The solution is washed successively with water, dilute hydrochloric acid, saturated aqueous sodium bicarbonate and brine and dried over magnesium sulfate. The solvent is evaporated in vacuo to give (2R, 4S, 5R) -4XI
with
about ate
four
i

Ca
 17310544
tert-butyldimethylsiloxymethyl-5-hydroxy-J 17.2 Hz); 4.93 (1H, fs, L 5 Hz);
2-methyl 1,3-dioxane (24.2 g) as 5.44 (1H, d „, L 17 Hz); 5.89 (1H, m),
colorless oil Solution (2R, 4K) 4-tert-butyldi
 H-NMR (CDClI), Gl-D: 0.10 (3N, j methyl-methyl-5-ethoxycarbonyl); 0.12 (3N, s); 0.91 (9H, s); 1.32methyl-2-methyl-1,3-dioxane (17.0 g)
(3H, fl, J - 5 Hz); 3.3 - 3.6 (3N, m); in ethanol (170 ml), shake under
3.7 - 3.8 (2H, m); 3.94 (1H, two-D, J nitrogen (3 atm) with 10% palladium
4.9 Hz); 4.13 (1H, dv, dn, L 5.9 Hz); on coal at room temperature
4.70 (1H, KB0, J 5 Hz) o10 jf5 h "After removing the solution by filtering (2RS 4S, 5K) -4 tert-butyl talizator, the solvent is evaporated
dimethylsiloxymethyl 5 hydroxy-2-methyl-in vacuo and the residue is subjected to chlor1,3-dioxane (4.2 g) in a benzene matography mixture on a silica gel column
(30 ml) and dimethyl sulfoxide (5.7 ml) (500 g) with a mixture of ntexane and ethyl supplement with pyridine (1.30 ml), three to 15 acetate (20: 1) as eluent and
phtoacetic acid (0.62 ml) and N, receive (2R, 4R, 53) -4-tert-butyl
N-dicyclohexylcarbodiimide (9.90 g) dimethylsiloxymethyl 5 ethoxycarbonyl
when cooled in an ice bath and a mixture of methyl 2 methyl 1,3-dioxane (9.52 g)
stirred for 3 hours at a mixture of light yellow oil;
The natural temperature is V20 (CDC1 "), & mln": 0.07
ethyl acetate (50 ml) (6H, 2co) was added; 0.89 (9H, s „); 1.26 (ZN, t.,
and water (30 ml) and stirred 30 7 Hz) 1 31 (ЗН д „J 5 Hz)
After removal of insoluble urea; 2 06 (iH, i), 43 (1H, m); 2.71 (1H,
filtration organic layer otde-dvd., L 10.16 Hz); 3.52 (1H, dvd.,
They are slumped and run sequentially in-25 tons - 11 tons% l. i JSC (li, „„ t J- /, Н1Ц, J, O: 7V.ln, DV. J. J -
Doi and brine ,, The solution is dehydrated 7 11 P ". about from / itr „„ t
- /, I I 1C, J, Oj VI i, DV I, o -
over magnesium sulfate, solvent.
evaporated in vacuo to give crude2 ™ 1 3.89 (H, two J 37 Hz);
butter. This oil is purified by column b-4 06 (2 Hz) (2N KV-
gel gel (50 g) (n-hexane: ethyl acetate 30 i (1H, q, L - b
ten ; 1) and get (2R, 43) -4-ter Solution (2R, 4R, 53) 4-tert-butylbutyl dimethylsilyloxymethyl-2-methyl-dimethylsiloxy-methyl 5-ethoxycarbonyl-
1,3-dioxane 5 it (3.22 g) in the form of light-methyl 2 methyl 1.3 dioxane (9.30 g)
lo-yellow oil "in toluene (93 ml) is cooled in dry
 n-NMR (CDCl5) pp: 0.07 (3N, s) ;, ice-cold acetone bath and solution
0.09 (3N, s); 0.89 (9H, c0); 1.47 (3N, diisobutylaluminum hydroxide is added dropwise
d, L 5S5 Hz); 3.98 (2H, dn, L -rida (1.5 M solution in toluene,
3.5 Hz); 4.3 4.5 (ЗН, m); 5.11 (1H, ml), the mixture is then stirred at
KB, J 5.5 Hz) at the same temperature of 1 h. After sharply
A mixture of (2R, 48) -4 tert butyldi-fi cooling the mixture using a
methylsiloxymethyl-2-methyl-1,3-dioxane-saturated aqueous ammonium chloride
5-she (2;, 50 g) and carboethoxymethylene — a mixture of ethyl acetateiphenylphosphorane (4.00 g) in tetrahydrate (300 ml) and water (300 ml) is added to the solution. Nerastrofuran (25 ml) is stirred at stolen substances are filtered off
24 hours and the solution — the filtrate is extracted with ethyl acetate and
The mixture is evaporated in vacuo. The residual organic layer is washed with brine
chromatographed on silica gel and dried over magnesium sulphate
le (50 g) with a mixture of n-hexane and ethyl-solvent is evaporated in vacuo and
acetate (YuM) as eluent and the residue is subjected to chromatography on
receive (2R, 4R) -4-TpeT 6yTmiflHMeTKri-silica gel column (250 g) with
siloxymethyl 5 ethoxycarbonylmethylene-mixture of n-hexane and ethyl acetate (10: 1)
2-methyl-1,3 dioxane (2.09 g) as eluent was used to obtain (2R, HR,
oils “5S) -4-tert-butyldimethylsiloxymethyl
H-NMR (CDCl), ppm: 0.08 (6H, 5-formylmethyl-2-methyl-1,3-dioxane
2c); 0.90 (9H, s) 5 ts38 (3H, To, J (6.61 g) as a colorless oil.
7.5 Hz); 1.47 (1H, fl., J - 5.0 Hz); 3.8355 (CDC16), J, ppm: 0.08
W, dv, d, L "9.11 Hz) 5 3.87 (1H, (6H, 2s); 0.88 (9H, s); 1.31 (ZN, d", L
dw ,, d, L and Hz); 4.17 (1H, KB., J 5.5 Hz); 2.19 (1H, m); 2.63 (1H, dvd.,
7.5 Hz); 4.30 (nG, m); 4.56 (1H, dd.d., J 5.17 Hz); 2.88 (1H ,, L,.
517
9.17 Hz); 3.50 (1H, dv.d., L 10.11 Hz 3.68 (1H,., L 7.11 Hz); 3.8 - 4.1 (MN, m); A, 74 (1H, sq., L - 5.5 Hz).
A suspension of sodium hydride (3.49 g; 60% in oil) in dimethyl sulfoxide (75 ml) is heated at 75 ° C for 1 h and the resulting solution is cooled to room temperature, the solution is added dropwise (4). Carbo sibutyl) triphenylphosphonium bromide (32.2 g) in dimethyl sulfoxide (100 ml) After stirring for 15 minutes at room temperature, (2R, 4R, 58) 4-tert-butyldimethyl soupyloxymethyl-5-1 ormylmethyl- 2-methyl-1,3-dioxane (6.3 g) in dimethyl sulfoxide (10 ml) and the solution is stirred at room temperature for 1.5 hours. The reaction mixture is added into ammonium chloride (100 ml) and the mixture is acidified to pH 4 with oxalic acid. The mixture is extracted with ethyl acetate and the organic layer is washed successively with water and brine and dried over magnesium sulfate. The solvent is evaporated in vacuo, the residue is chromatographed on silica gel (150 g) with a mixture of n-hexane and ethyl acetate (10: 1 - 1: 1) as eluent, to obtain (2R, 4R,) 4-tert-butyldimethylsiloxymethyl- 5- (Z) -6-carboxy-hexyl) -2- methyl 1,3-dioxane (5.50 g) as a colorless oil.
H-NMR (CDC1) ,, ppm: 0.07 (6H, 2s); 0.89 (9H, s); 1.31 (ZN, d0, L 5 Hz); 1.50 (1H, m.); 1.6 - 1.8 (2H, m); 2.0 - 2.2 (ЗН, m); 2.3 - 2.6 (ЗН, m); 3.5 - 3.8 (ЗН, m); 3.89 (1H, m); 4.02 (1H, d, L 11 Hz); 4.73 (1H, KBo, J 5 Hz); 5.3 - 5.6 (2H, m „)“,
Into a solution of (2R, 4R, 55) -4-treT-butyldimethylsiloxymethyl-5- | (Z) -6-carbox-2-hexen-6-2-methyl-1,3-dioxane (4, 75 g) in N, N-dimethylformamide (50 ml) potassium carbonate (1.76 g) and methyl iodide (1.62 ml) are added and the mixture is stirred at room temperature for 5 hours. The solution is poured into water and the resulting aqueous solution is extracted ethyl ether The organic layer is washed successively with water, brine and dried over magnesium sulfate. The solvent is evaporated in vacuo and the residue is chromatographed on silica gel (75 g) with a mixture of n-hexane and ethyl acetate. (20: 1) as an eluent to give (2R, 4R, 5S) -
0
0
five
0546
4-tert-butyldimethylsiloxymethyl-5- (g) -6-methoxycarbonyl-2 hexenyl | -2-methyl-1,3-dioxane (4.17 g) as mayel.
 n-NMR (CDCl 3), 0.07 (6H, 2s,); 0.96 (9H, s.); 1.31 (ZN, d, L 5 Hz); 1.48 (1H, m); 1.6 - 1.8 (2H, m „); 2.0 - 2.2 (ЗН, m „); 2.3 - 2.6 (ЗН, m.); 3.5 - 3.7 (ЗН, m.); 3.68 (ЗН, m,); 3.89 (1H, M); 4.00 (1H, d, L 22 Hz); 4.72 (1H, KB., J 5 Hz); 5.3 - 5.6 (2H, mn). To a solution of pyridine (1.64 ml) in dichloromethane (45 ml) is added trioxide
5 chromium (1.07 g) at, 10 ° С and solution
stirred at room temperature for 1 h. The solution was cooled in an ice bath, and (2R, 4R, 5S) -4 oxymethyl-5-Ј (Z) -6-methoxycarbonyl-2-hexenyl} -2-methyl-1 was added to it. , 3-dioxane (500 mg) in dichloromethane (3 ml). After stirring at room temperature for 2 h, the solution is diluted with ethyl ether (100 ml) and passed through a silica gel column. The eluate is evaporated in vacuo and the residue is chromatographed on silica gel (20 g). with a mixture of n hexane and ethyl acetate (1: 1) as eluent, to give (2R, 4R,
0 58) -4-formyl 5-G (2) 6-methoxycarbonyl 2 hexane -2-methyl-1,3-dioxane (336 mg) as a colorless oil,
 n-NMR (AHSC), Ј, ppm: 1.43 (ZN, d, L 5.5 Hz); 1.5 - 1.8 (ЗН, m „); 1.91 (1H, Mo); 2.0-2.2 (2H, m); 2.3 - 2.4 (ЗН, m,); 2.55 (1H, m); 3.69 (ZN, p.); 3.78 (1H, m); 4.03 (1H, dd.d, L 2.11 Hz); 4.27 (1H, d ,, L 2 Hz); 4.80 (1H, KB0, J 5.5 Hz); 5.3 - 5.6
0 (2H, m); 9.62 (1H, s)
To a mixture of (2R, 4R, 58) -4-formyl 5 (Z) -6-methoxycarbonyl-2-hexenyl-2-methyl-1,3-dioxane (62 ml) and 4-phenyl-
g of 3-thiosemicarbazide (46 mg) in ethanol (2 ml) was added acetic acid (1, drop) and the solution was stirred at room temperature for 4 hours. The mixture is diluted with chloroform (15 ml), solution
0 is washed with brine and dried over magnesium sulphate. The solvent is evaporated in vacuo to give (2R, 4R, 58) -5-j (Z) -6-methoxycarbonyl-2t exelen-2-methyl-4- 4- (phenyl) - tiosemi-
carbazonomethyl -1,3-dioxane (110 mg) as an oil
H-NMR (CBC: C), Ј, ppm, d: 1.38 (3N, d, L 5 Hz); 1.5 - 1.8 (ЗН, m.); 2.0-2.1 (3N, m); 2.2 - 2.4 (2H, m „);
five
2.53 (1H, m.); 3.69 (ZN, ss); 3.85 (1H, MO); 3.85 (1H, Mo); 5.04 (1H., M.); 4.53 (1H, Dd, L 3-4.5 Hz); 4.82 (1H, m.); 5.3 - 5.6 (2H, Mo); 7.2 - 7.5 (4H, Mo); 7.62 (ЗН, m.); 9.04 (1H, Co); 9.73 (1H, Co) o
A solution of (2R, 4R, 5S) -5-Ј (Z) -6-Me-toxycarbonyl-2-hexenyl -2-methyl-4-4- (phenyl) thiosemicarbazonomethyl - 1,3-dioxane (110 mg) in a mixture methanol (2 ml) and 1 HO sodium hydroxide (1 ml) is stirred at room temperature for 2 hours and the mixture is acidified to pH 7 with 1 and hydrochloric acid. The solvent is evaporated in vacuo and the residue is dissolved in a mixture of chloroform and methanol (3: 1.10 ml) o The solution is dried over magnesium sulphate, the solvent is evaporated in vacuo and a crude oil is obtained. This oil is purified by preparative thin-layer chromatography to give (2R, 4R, 58) -5- (g) -6-carboxylic acid Force-2-hexenyl, 2-methyl 4- (phenyl) thio semikarbazonometil) -1,3 dioxane (65 mg) as an oil
 (CDC13), & mlnD: 1.42 (3N, A «, J - 5 Hz); 3.88 (1H, flo, J 11.52 Hz); 4.10 (1H, fl., J 11.5 Hz); 4.56 (1H, flBoflo, J 2.3); 4.83 (1H, q "J 5 Hz; 5.55 (2H, m0); 7.2 - 7.2 (6H, Mo); 9.07 (1H, s"); 10.8 (1H,
SHIR about S about) about
A solution of (2R, 4R, 5S) -5-L (Z) boxy-2-hexenst -2-methyl-4 1.4- (phenyl) thiosemicarbazonomethyl -1,3-dioxane (1.39 g) in a mixture methanol (10 ml and 1 HO aqueous sodium hydroxide (3.43 ml) is stirred at room temperature for 2 hours and the solvent is evaporated in a vacuum. The residue is dissolved in water (50 ml) and the solution is treated on a Diaion HP-20 column (trademark, sold by Mitsubishi Chemical Industries) (200 ml} 0 The column is washed with water (500 ml) and the target compound is eluted with a mixture of water and methanol (, 1 l) o The solvent is condensed in a vacuum and the residue is lyophilized to obtain (2R, 4R, 5S) -5- Ј (g) -6-carboxy 2-hexenyl,} 2-methyl- (phenyl) 1 thiosemicarbazonometh - 1,3-dioxane sodium salt (1.77 g) as a light yellow powder,
 H-NMR (D20), 5 ppm: 1.39 (GH, fl., J 5.5 Hz); 1.5 - 1.73 (H, M.) J 199 - 2.1 (3H, M,) j 2.1 - 2.3 (4H, M.) I 2.37 (1H, m.); 4.05 (1H, s.); 4.98 (1H,

10548
quo.L 5.5 Hz); 4.8 - 5.1 (2H, m „); 7.3 - 7.5 (6H, Mo) o
The proposed compound and its pharmaceutically acceptable salt are antagonists of thromboxane A2 (TXA2) and therefore useful as therapeutic substances for the treatment of diseases caused by TXA (e.g. thrombosis, asthma and) „.
In the following tests, the used 9,11-azo PGH and 9,11-methanoepoxy PGH (U 46619) are pharmacologically characterized as simulators H &amp; H and are widely used for test compounds.
The effect on PGHg caused by 9,11-azo, platelet aggregation in rabbit in vivo is studied by comparing compound (I)
ten
15
20
CH:
Q.- A / SCOOH
, A. A.) lmnpin- / L
(about
and the perverted compound of formula (II)
behind
 i, -,
(2)
five
The effect on in vitro 9,11-azo PCNg platelet accumulation of rabbit is studied as follows. In in vitro experiments, blood
0 are collected from the rabbit carotid artery into plastic vessels containing 0.1 volumes of 3.8% aqueous sodium citrate. Platelet-rich plasma (PRP) is obtained by centrifugal
5 with 150 g for 15 min. Platelet accumulation is examined by the turbidimetric method using an aggregometer (NKK HEMATRACEP 1). In a 225 µl PRP, 25 µl solution is added.
Q of the compound to be tested and then stirred at a speed of 1000 rpm. in 1 min for 2 min at 37 ° C. To this solution, 5 µl of 9,11-azo PCNg (finally 1.0 µM) was added as an aggregation inducer. Graphically determined (concentration of inhibition of platelet aggregation by 50%). The test results are shown in table 1.
Effect on induced 9,11 methano-epoxy PGH. ex vivo platelet aggregation is investigated by the following procedure,
In ex vivo experiments, male guinea pigs of the Hartley species weighing 300 g are used after starving overnight. Animals are orally administered to the test compound or vehicle 1 hour before blood is collected from the abdominal artery. In the same way as described above, PRP was prepared and cause platelet aggregation using an Additive of 5 µl of 9,11-methanoepoxy PGHfc (U 46619,0,5 µM) in 250 µl of PRP.
The test results are presented in Table „2„
Table 2

权利要求:
Claims (1)
[1]
Invention Formula
The method of producing 1,3-dioxane derivatives of the general formula
Q x.x GH 2
RA X Rgmn- /
I
where RJ is lower alkyl;
R- is lower alkyl substituted by carb o xygroup,
or salts thereof, characterized in that the compound of the general formula
nx-v Ha-CH CK-R Rl 0I MNHCHH
Acute Toxicity Test
carried out according to the following method
After the mice of the JCR strain (one group — five animals) were suspended using a dental method
where Rj has the indicated value; R is lower alkyl substituted by protected carboxy (lower) alkyl,
subjected to the removal of the carboxy-protective group by hydrolysis and isolate the target product in free form or as a salt,

类似技术:

---

公开号 | 公开日 | 专利标题

---

CA1265517A|1990-02-06|.alpha.-[2-OXO-2,4,5,6,7A-HEXAHYDRE-|THIENO-5-PYRIDYL] PHENYL ACETIC ACID DERIVATIVES;PROCESS FOR PREPARING THE SAME AND THEIR USE ASTHERAPEUTIC AGENTS

---

FR2488890A1|1982-02-26|TRICYCLIC DERIVATIVES OF IMIDAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC USES

---

FR2530247A1|1984-01-20|NOVEL THIENO | PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

---

US4032534A|1977-06-28|Certain 2-|thiazolidine-4-carboxylic acids

---

FR2601016A1|1988-01-08|NOVEL 1H, 3H-PYRROLO | THIAZOLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

---

FI92198B|1994-06-30|Process for the preparation of pharmacologically valuable 2- | -substituted 2,3-dihydro-5-oxy-4,6,7-trimethylbenzofurans

---

FR2472574A1|1981-07-03|CEPHALOSPORINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

---

SU1480763A3|1989-05-15|Method of producing derivatives of 1-surfo-2-oxoazetidinone or their salts or esters

---

US4113873A|1978-09-12|8-azaprostanoic acid derivatives

---

SU1731054A3|1992-04-30|Process for preparing 1,3-dioxane derivatives or salts thereof

---

SU1277900A3|1986-12-15|Method of producing 5-|-1h,3h-pyrrole/1,2-c/-7-thiazolcarboxaldehyde

---

SU1266472A3|1986-10-23|Method of producing |-7/3-3-|-h,3h-pyrrole-|-thiazole

---

FR2605319A1|1988-04-22|PROSTAGLANDIN-SUBSTITUTED 7-OXABICYCLOHEPTANE HYDROXAMIC ACIDS WITH THERAPEUTIC ACTION.

---

JP4877664B2|2012-02-15|HEALTH FOOD FOR PREVENTION OR IMPROVEMENT OF THROMBOSIS AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF THROMBOSIS

---

US5750524A|1998-05-12|Remedy for hyperlipidemia

---

EP2054419A2|2009-05-06|Pyrimidinone derivatives and their use as a drug

---

FR2464254A1|1981-03-06|OXOIMIDAZOLINALCANOIC ACIDS, THEIR SALTS AND ESTERS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM

---

US5096917A|1992-03-17|Substituted indoles

---

US4963580A|1990-10-16|Substituted 5-hydroxy-2,3-dihydrobenzothiophenes as inhibitors of leukotriene biosynthesis

---

US5162352A|1992-11-10|7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs

---

US4171375A|1979-10-16|Cyclopentane derivatives and their pharmaceutical compositions

---

EP0043205B1|1984-09-26|Penicillin derivatives

---

BE897156A|1983-12-28|DITHIOIAN DERIVATIVES, THEIR PREPARATION AND THEIR USE

---

FR2536074A1|1984-05-18|NEW CEPHALOSPORINS, PROCESSES FOR PREPARING THEM, ANTIBACTERIAL AGENTS CONTAINING SAME, INTERMEDIATES FOR THEIR PREPARATION, AND PROCESS FOR THE PREPARATION OF INTERMEDIATES

---

DD146046A5|1981-01-21|PROCESS FOR THE PREPARATION OF AURON DERIVATIVES

同族专利:

---

公开号 | 公开日

---

EP0346511A1|1989-12-20|

---

AU1774688A|1990-01-18|

---

US4929639A|1990-05-29|

---

AU615449B2|1991-10-03|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4243592A|1979-03-12|1981-01-06|The Upjohn Company|9,11-Dideoxy-10-oxa-TXB compounds|

---

GB8310407D0|1982-05-12|1983-05-25|Ici Plc|1 3 - dioxan -5- ylalkenoic acids|US5053425A|1990-03-21|1991-10-01|Merck & Co., Inc.|Novel anti-fungal compounds|

---

US5055487A|1990-03-21|1991-10-08|Merck & Co., Inc.|Novel anti-fungal compounds|

---

GB9021571D0|1990-10-04|1990-11-21|Ici Plc|Heterocyclic acids|

---

BRPI0806686A2|2007-01-18|2014-11-04|Evolva Sa|COMPOUNDS AND ITS USES, METHODS OF TREATMENT OR PREVENTION, PHARMACEUTICAL COMPOSITIONS AND CRYSTALLINE COMPOUND AND SOLVAT|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

EP88109527A|EP0346511A1|1988-06-15|1988-06-15|Oxygen-containing hererocyclic compound, processes for their preparation and pharmaceutical compositions comprising them|

---